en · de · es · pt
bench-notes.peptides6579.com › Data › Bremelanotide Background And Receptor Pharmacology — Background and Details

Bremelanotide Background And Receptor Pharmacology — Background and Details

By Editorial Desk · published 2025-12-05 · last reviewed 2026-01-09 · Data

The short version of Cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-01-09. Anything still debated is marked as such rather than presented as settled.

Bremelanotide Background and Receptor Pharmacology

Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.

PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.

Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.

Bremelanotide Identity and Background

Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.

Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.

Pt-141 at a glance

PropertyValueNotes
Research codePT-141Used in early literature before the generic name became common
Generic nameBremelanotideInternational nonproprietary name
Peptide classCyclic heptapeptideSeven residues joined by a lactam bridge
Primary receptorMC4RLower affinity reported at MC1R, MC3R and MC5R
Route studied clinicallySubcutaneous injectionIntranasal route was abandoned after pressor effects

Bremelanotide Naming and Background

Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.

Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.

Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.

Related pages on this site

Identity and Chemical Background

Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.

Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.

Reference notes

Other experiments have demonstrated that the formation of perchlorate is associated with wide band gap semiconducting oxides. In 2014, it was shown that perchlorate and chlorate can be produced from chloride minerals under Martian conditions via UV using only NaCl and silicate. Further findings of perchlorate and chlorate in the Martian meteorite EETA79001 and by the Mars Curiosity rover in 2012-2013 support the notion that perchlorates are globally distributed throughout the Martian surface. With concentrations approaching 0.5% and exceeding toxic levels on Martian soil, Martian perchlorates would present a serious challenge to human settlement, as well as microorganisms. On the other hand, the perchlorate would provide a convenient source of oxygen for the settlements. On September 28, 2015, NASA announced that analyses of spectral data from the Compact Reconnaissance Imaging Spectrometer for Mars instrument (CRISM) on board the Mars Reconnaissance Orbiter from four different locations where recurring slope lineae (RSL) are present found evidence for hydrated salts. The hydrated salts most consistent with the spectral absorption features are magnesium perchlorate, magnesium chlorate and sodium perchlorate. The findings strongly support the hypothesis that RSL form as a result of contemporary water activity on Mars.

=== Acidity === Carboxylic acids are Brønsted–Lowry acids because they are proton (H+) donors. They are the most common type of organic acid. Carboxylic acids are typically weak acids, meaning that they only partially dissociate into [H3O]+ cations and R−CO−2 anions in neutral aqueous solution. For example, at room temperature, in a 1-molar solution of acetic acid, only 0.001% of the acid are dissociated (i.e. 10−5 moles out of 1 mol). Electron-withdrawing substituents such as trifluoromethyl (−CF3) give stronger acids (the pKa of acetic acid is 4.76 whereas trifluoroacetic acid, with a trifluoromethyl substituent, has a pKa of 0.23). Electron-donating substituents give weaker acids (the pKa of formic acid is 3.75 whereas acetic acid, with a methyl substituent, has a pKa of 4.76)

=== Advancements in fluid flow analysis === Inviscid flow was further analyzed by various mathematicians (Jean le Rond d'Alembert, Joseph Louis Lagrange, Pierre-Simon Laplace, Siméon Denis Poisson) and viscous flow was explored by a multitude of engineers including Jean Léonard Marie Poiseuille and Gotthilf Hagen. Further mathematical justification was provided by Claude-Louis Navier and George Gabriel Stokes in the Navier–Stokes equations, and boundary layers were investigated (Ludwig Prandtl, Theodore von Kármán), while various scientists such as Osborne Reynolds, Andrey Kolmogorov, and Geoffrey Ingram Taylor advanced the understanding of fluid viscosity and turbulence.

=== Health care === Albany is served by Samaritan Albany General Hospital, a 76-bed medical facility that is the main hospital for the city and has been in operation since 1924. Albany is also served by Samaritan North Albany Urgent Care and Geary Street Urgent Care, both of which are part of Samaritan Health Services. The unaffiliated Albany Family & Specialty Medicine also provides medical services to the community.

== Attempted murder trials == In 1982, von Bülow was arrested and tried for the attempted murders of Sunny on two occasions in two consecutive years. The main medical and scientific evidence against him was that Sunny had low blood sugar, common in many conditions, but a blood test showed a high insulin level. The test was not repeated. A needle was used as evidence against von Bülow in court, with the prosecution alleging that he had used it and a vial of insulin to try to kill his wife. His mistress of two years, the soap opera actress Alexandra Isles, testified "He said that they had been having a long argument, talk, about divorce that had gone on late into the night. She had drunk a great deal of eggnog. And then he said, 'I saw her take the Seconal.' And then he said that the next day when she was unconscious that he watched her knowing that she was in a bad way, all day, and watched her and watched her. And finally, when she was at the point of dying, he said that he couldn't go through with it and he called (the doctor) and saved her life." The discovery of these items became the focal point of von Bülow's appeal. At the trial in Newport, Rhode Island, von Bülow was found guilty and sentenced to 30 years in prison; he appealed, hiring Harvard Law School professor Alan Dershowitz to represent him. Dershowitz served as a consultant to the defence team led by Thomas Puccio, a former federal prosecutor.

Sources: en.wikipedia.org

Reference notes

The second-generation semisynthetic β-lactam antibiotic methicillin, designed to counter first-generation-resistant penicillinases, was introduced in the United Kingdom in 1959. Methicillin-resistant forms of S. aureus (MRSA) were first observed in the UK in 1960, less than a year later. It is likely that MRSA strains already existed many years before methicillin was introduced. This demonstrated that new drugs intended to circumvent known resistance mechanisms could be rendered ineffective by bacterial adaptations caused by the widespread use of other antibiotics.

=== Souvenirs and general merchandise === Besides food and drinks, the company offers a variety of general and regional-based souvenirs, including apparel and artwork featuring their logo and mascot. The chain carries its own clothing brand, ranging from t-shirts to hats, beanies, pants, plushies, swimwear, and blankets. Stores also carry general kitchen goods: cast iron skillets, food containers, mugs, glassware, cookbooks, coolers, and vacuum flasks, among other items. General travel products are sold along with phone accessories. Various locations sell hunting gear and equipment alongside outdoor products like grills and fire pits.

It has been proposed that ubiquitin is the slowest-evolving protein identified to date. Ubiquitin contains seven lysine residues to which another ubiquitin can be ligated, resulting in different types of polyubiquitin chains. Chains in which each additional ubiquitin is linked to lysine 48 of the previous ubiquitin have a role in proteasome targeting, while other types of chains may be involved in other processes.

=== Personality === Her structural studies of biologically important molecules set standards for a field that was very much in development during her work life. She made contributions to the understanding of how these molecules carry out their tasks in living system.

== Literary and cinematic portrayals == Lobotomies have been featured in several literary and cinematic presentations that both reflected society's attitude toward the procedure and, at times, changed it. Writers and filmmakers have played a pivotal role in turning public sentiment against the procedure.

Sources: en.wikipedia.org

Reference notes

Numerous Jamaicans migrated mainly to the islands of San Andres and Providencia. A number of other Europeans and North Americans migrated to the country in the late 19th and early 20th centuries, including people from the former USSR during and after the Second World War. Many immigrant communities have settled on the Caribbean coast, in particular recent immigrants from the Middle East and Europe. Barranquilla (the largest city of the Colombian Caribbean) and other Caribbean cities have the largest populations of Lebanese, Palestinian, and other Levantines. There are also important communities of Romanis and Jews. There is a major migration trend of Venezuelans, due to the political and economic situation in Venezuela. In August 2019, Colombia offered citizenship to more than 24,000 children of Venezuelan refugees who were born in Colombia.

Rindo Azami (阿左美 竜胆, Azami Rindō) Voiced by: Taku Yashiro (Japanese); Lee George (English) The Agent of Autumn's Guard. He treats his job like a business, without letting his emotions get in the way. Those around him don't see it that way. He doesn't realize it, but he's overprotective of Nadeshiko.

==== Electronic structure ==== Plutonium is an element in which the 5f electrons are the transition border between delocalized and localized; it is therefore considered one of the most complex elements. The anomalous behavior of plutonium is caused by its electronic structure. The energy difference between the 6d and 5f subshells is very low. The size of the 5f shell is just enough to allow the electrons to form bonds within the lattice, on the very boundary between localized and bonding behavior. The proximity of energy levels leads to multiple low-energy electron configurations with near equal energy levels. This leads to competing 5fn7s2 and 5fn−16d17s2 configurations, which causes the complexity of its chemical behavior. The highly directional nature of 5f orbitals is responsible for directional covalent bonds in molecules and complexes of plutonium.

These developments led to advances in the field of evolutionary developmental biology towards understanding how the various body plans of the animal phyla have evolved and how they are related to one another. The Human Genome Project—the largest, most costly single biological study ever undertaken—began in 1988 under the leadership of James D. Watson, after preliminary work with genetically simpler model organisms such as E. coli, S. cerevisiae and C. elegans. Shotgun sequencing and gene discovery methods pioneered by Craig Venter—and fueled by the financial promise of gene patents with Celera Genomics— led to a public–private sequencing competition that ended in compromise with the first draft of the human DNA sequence announced in 2000.

Sources: en.wikipedia.org

Frequently asked questions

What does the PT-141 code refer to?

The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.

Which receptor is considered the principal target?

MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.

How does it relate to melanotan II?

Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.

What class of compound is this?

It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.

Network